articleTop 10% cited
Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer – results of the ALMANAC validation phase
Breast Cancer Research and Treatment · 2006 · Vol. 99(2) · pp. 203–208
Amit Goyal(University of Wales)Robert G. Newcombe(Cardiff University)Alok Chhabra(University of Wales)Robert E. Mansel✉(Cardiff University)on behalf of the ALMANAC Trialists Group
Breast Cancer Treatment StudiesBreast Lesions and CarcinomasBreast Implant and ReconstructionMedicineSentinel lymph nodeBreast cancerBiopsySentinel nodeAxillaProspective cohort studyLymph nodeNuclear medicineCancer
MeSH terms
AdultAgedAged, 80 and overAxillaBreast NeoplasmsFalse Negative ReactionsFemaleHumansLymph NodesLymphatic MetastasisMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPredictive Value of Tests
Citations
328
FWCI
5.51
field-weighted impact
References
18
Percentile
96%
vs. same field & year
Citations per year
Cited by
Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC Trial
JNCI Journal of the National Cancer Institute · 2006 · 1,660 citations
References
Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC Trial
JNCI Journal of the National Cancer Institute · 2006 · 1,660 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.